ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer

Over the past 2 years, the use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has become the standard of care for these patients. The first combination was nivolumab plus ipilimumab, which demonstrated a survival benefit over sunitinib in patients with intermediate and poor risk metastatic RCC (CheckMate-214). Shortly after, […]

read more

Association between TKI-induce high blood pressure and outcomes in patients with kidney cancer

In this retrospective study published in Cancer Reports the association between TKI-induced high blood pressure (hypertension) and treatment outcomes was reported. Fifty-two (52) patients with metastatic renal cell carcinoma (RCC) treated with first-line sunitinib, pazopanib, sorafenib, axitinib, or cabozantinib were examined for any association between TKI-induced hypertension and treatment outcomes. The study found that patients […]

read more

Platelet-to-lymphocyte ratio predicts survival outcomes in kidney cancer

In this study, the researchers looked at the association between a high platelet-to-lymphocyte ratio in the blood and the prognosis of patients with metastatic renal cell carcinoma (RCC). Data from 1,505 patients with metastatic RCC were retrospectively analysed. There were 921 patients with a high platelet-to-lymphocyte ratio and and 584 patients with a low ratio. […]

read more

Outcomes of complete metastasectomy in metastastic kidney cancer

A recent study from Canada investigated the use of surgery to remove metastases (metastasectomy)  as part of the treatment of metastatic renal cell carcinoma (RCC) and whether this delayed progression of the disease and improved survival. Real world data from 229 Canadian patients was used in this study. These data were matched with 803 control […]

read more

Circulating tumour DNA as a potential prognostic biomarker for immunotherapy

A study published in Nature Cancer showed that blood levels of DNA from solid tumours (circulating tumour DNA or ctDNA) were associated with the prognosis of cancer patients with different types of  tumours who had been treated with pembrolizumab. The study included 94 patients with various solid tumours who were treated with pembrolizumab. ctDNA levels varied […]

read more

Cabozantinib after immunotherapy in advanced kidney cancer

This recent retrospective study included 84 patients with metastatic renal cell carcinoma (RCC) who were treated with cabozantinib after being treated with nivolumab. Most of the patients had poor- or intermediate-risk RCC and all patients received a tyrosine kinase inhibitor (TKI) as first-line therapy, followed by nivolumab in the second- or third-line. Median progression-free survival […]

read more

Blood tumour biomarker for kidney cancer survival

Researchers are constantly looking for biomarkers to help predict which patients will respond to each kidney cancer treatment. A study in Scandinavia has discovered a protein called tumour associated trypsin inhibitor (TATI) that is a biomarker for several tumours and for inflammation. High levels of TATI in the blood predicts an unfavourable outcome for many […]

read more

Safety and efficacy of nivolumab for non-clear cell kidney cancer

Nivolumab alone and in combination with ipilimumab is used for the treatment of patients with metastatic renal cell carcinoma (RCC). However, most patients with non-clear cell RCC are excluded from clinical trials, and there is limited data on the effectiveness of nivolumab for the treatment of these patients. This phase IIIb/IV CheckMate 374 study was conducted to look at […]

read more

Clinical outcomes of first-line sunitinib followed by immunotherapy

A recent study published in Clinical Genitourinary Cancer has found that the use of first-line sunitinib did not have any influence on the effectiveness of second-line immunotherapy for patients with metastatic renal cell carcinoma (RCC). The researchers found no statistically significant association between the duration of the use of first-line sunitinib and clinical outcomes with […]

read more

Survival outcomes for patients on ipilimumab plus nivolumab combination therapy

Further results from the ongoing CheckMate 214 phase III study have been released. In this study, 550 patients with advanced renal cell carcinoma (RCC) were randomised to receive ipilimumab plus nivolumab and 546 were randomised to be treated with sunitinib. Patients with intermediate- or poor-risk RCC responded well to ipilimumab plus nivolumab and progression-free and […]

read more
Showing 1 to 10 of 120 results
  TOP